In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Novo Nordisk, Aradigm end pulmonary insulin delivery deal

Executive Summary

Novo Nordisk and Aradigm will co-develop a pulmonary delivery system, based on the latter company's AERx technology, for the administration of insulin, and potentially other blood glucose regulating compounds, through inhalation.
Deal Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
    • Drug Delivery
      • Pulmonary
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Includes Contract
    • Includes Equity
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register